Lilly's injectable diabetes drug receives FDA approval

This drug is said to be in competition with exenatide (AstraZeneca), albiglutide(GSK) and liraglutide (Novo Nordisk)


This marks the first approval for Trulicity anywhere in the world

Trulicity (dulaglutide) was approved by USFDA, which is the latest Eli Lilly's treatment option for adults with type 2 diabetes.

Diabetes remains one of society's most prevalent diseases. More than 380 million people around the world suffer from diabetes.

Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Trulicity comes in a single-dose pen that does not require mixing, measuring or needle attachment. It is administered once a week, any time of day, independent of meals, and should be injected subcutaneously in the abdomen, thigh or upper arm.

The recommended starting dose is 0.75 mg, which can be increased to 1.5 mg dose for patients who need additional blood sugar control.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email